Clinical Trial

JSKN022 in Subjects With Advanced Malignant Solid Tumors

Name: JSKN022 in Subjects With Advanced Malignant Solid Tumors — clinical trial record (NCT07292402)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to learn if drug JSKN022 is safe to treat patients with advanced malignant solid tumors. It will also learn about the pharmacokinetic/ pharmacodynamic profiles and preliminary antitumor activity of drug JSKN022.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-12-16.

Trial Details

NCT Number	NCT07292402
Lead Sponsor	Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Conditions	Advanced Malignant Solid Tumors
Enrollment	225 participants
Start Date	2025-10-23
Primary Completion	2027-08-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-23